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INTRODUCTION 
The role of the respiratory system is to ensure adequate exchange of oxygen and carbon dioxide for 
ƚŚĞ ďŽĚǇ ?Ɛ ŵĞƚĂďŽůŝĐ ƌĞƋƵŝƌĞŵĞŶƚƐ ? dŚis process of gas exchange requires adequate ventilation, passive 
diffusion across the alveolar surface and pulmonary perfusion. The assessment of pulmonary perfusion is 
therefore important in further understanding multiple physiological and pathophysiological mechanisms 
and also in the diagnosis and follow up of multiple pulmonary diseases.  
There are two broad approaches in MR imaging of the pulmonary circulation. Higher spatial, but 
lower temporal resolution MR angiography (MRA) allows for assessment of the structure of the pulmonary 
arterial and venous system. Whilst lower spatial but higher temporal resolution perfusion MRI allows for 
the assessment of capillary level tissue perfusion (1).  
Current clinical practice relies upon CTPA for the structural analysis of the pulmonary vasculature: it 
is readily available, fast, cheap and offers high spatial resolution. However, it requires exposure to 
approximately 5 mSv of ionising radiation, which is associated with increased risk of cancer and requires 
the use of iodinated contrast media, which is contraindicated in allergy or renal failure. Single photon 
emission computed tomography (SPECT) is currently the mainstay of clinical perfusion imaging. This 
requires injection of 100MBq of 99mTc labelled macro-aggregated human albumin, resulting in exposure 
to ionising radiation with an effective dose of 3mSv (2). Beyond exposure to ionising radiation the 
limitations of SPECT include: low spatial and temporal resolution, soft tissue attenuation (for example 
breast tissue or obesity) and movement from the diaphragm.  
Historically, pulmonary MRI has been limited by poor signal due to: low proton density; 
susceptibility differences between multiple air-tissue interfaces causing short T2*; and motion artefact 
from the heart and breathing (1,3,4). However, improvements in scanner hardware and short echo time 
pulse sequences combined with parallel imaging and view sharing techniques have allowed for reduced 
acquisition times, counteracting the short T2* and movement artefacts.  Imaging of pulmonary perfusion 
and particularly its quantification is further complicat
physiological differences in pulmonary blood flow in expiration and inspiration (1). Furthermore there are 
anatomical differences in regional perfusion due to gravity, causing an apico-basal gradient when erect (5) 
or an antero-posterior gradient when supine (6). This perfusion heterogeneity is reduced in the prone 
position (7). Consideration is also required of the dual circulatory systems in the lungs: the pulmonary 
arteries carry deoxygenated blood from the right ventricle to the lungs to be oxygenated and the bronchial 
arteries carry oxygenated blood from the aorta to supply the pulmonary parenchyma with its metabolic 
requirements (1). Moreover, the pulmonary arteries and veins have a similar anatomical distribution and 
can be hard to distinguish so it is therefore important to ensure that the correct  “phase ? of blood flow is 
imaged. MRI of the lungs is also further constrained by patient factors: patients who are short of breath 
may not be able to breath-hold for much longer than 10 seconds and patient positioning and 
claustrophobia can also lead to scanning difficulties with movement artefacts or abortion of scans. 
CONTRAST ENHANCED METHODS 
 
CONTRAST ENHANCED MRA 
 
T1 shortening contrast agents can be used to produce high spatial resolution images of the 
pulmonary arteries and veins with 3D acquisitions within a single breath-hold. Currently this method is the 
mainstay of pulmonary MRA in the clinical setting. Typically, a bolus of gadolinium-chelated agent is 
administered into a large vein, usually in the antecubital fossa followed by a saline flush. Typical contrast 
doses are 0.1 mmol/kg body weight Gadovist followed by a 20ml saline flush injected at 5ml/sec. In order 
to reduce venous contamination and gain greatest arterial and venous separation, a single dose of 
gadolinium at a high injection rate should be used. 
The contrast administration is followed by acquisition of a T1 weighted 3D gradient echo dataset. 
Typical imaging parameters are: TR=2.5-3 ms, TE=1.0- ? ? ?ŵƐ ?ɲA? ? ?-40°, matrix=40×192×256, FOV=460 mm, 
parallel imaging factor R=2 (3). In order to synchronise image acquisition with peak contrast enhancement 
in the pulmonary vessels, a bolus tracking technique can be employed: a test bolus with a time resolved 
test scan is used to assess the optimal time from injection to acquisition of central k-space, resulting in 
images from a single time point (3). An important consideration in pulmonary MRA is the rapid transit of 
blood through the lungs (3-5 seconds). Centric elliptic phase encoding, with the scan acquisition starting at 
peak enhancement ensures maximum SNR and optimal separation of arterial and venous phases. 
The contrast bolus passage may also be imaged with time resolved 3D view sharing acquisitions, 
such as TRICKS (Time Resolved Imaging of Contrast KineticS), allowing for haemodynamic assessment of 
the pulmonary circulation. These view-sharing methods under-sample k-space and share missing k-space 
between datasets, giving a higher nominal temporal resolution, with the risk of spatio-temporal 
interpolation artefacts. Other methods for k-space sampling such as spiral acquisition and view sharing can 
further reduce scan times, with some centres producing high spatial resolution MRA images with temporal 
resolution of 1 second through spiral-TRICKS acquisition (8). 
Whilst the majority of clinical MRA is currently performed using extracellular contrast media such 
as gadobutrol (Gadovist TM) and gadobenate dimeglumine (Multihance TM), there is also the potential to 
perform pulmonary MRA using intravascular (blood pool) media such as Gadomer-17,  Gadofosveset 
trisodium and ferumoxytol (9). The long residency time of these agents can enable high SNR and spatial 
resolution with averaging over several breath-holds, however arterial and venous phase separation is 
sacrificed (9). Blood pool agents for clinical pulmonary MRA is very helpful in patients that cannot hold 
their breath as non breath-hold heavily averaged MRA acquisition methods can be used. 
DYNAMIC CONTRAST ENHANCED PERFUSION MRI 
 
With a similar methodology to contrast enhanced MRA but using lower spatial and higher temporal 
resolution image acquisition, T1-weighted dynamic contrast enhanced (DCE) perfusion images of the first 
pass of a gadolinium contrast bolus can be performed. Typical imaging parameters would be: TR=2.0-
2.5ms, TE=0.8-  ? ? ?ŵƐ ?ɲA? ? ?-40°, matrix=32×96×128, FOV=460mm. A lower dose of contrast is needed e.g.  
0.05ml per kg patient weight of gadobutrol (Gadovist TM). Again, the nominal temporal resolution of the 
acquisition can be increased with parallel imaging and view sharing (1) but this can result in spatio-
temporal blurring of the signal. In clinical practice, images acquired with a frame rate of around 0.5 s per 
3D lung volume can preserve spatial resolution sufficient for diagnostic purposes. 
Perfusion images can be qualitatively assessed by subtraction of the baseline dataset from the peak 
enhancement dataset, allowing for a rapid assessment of perfusion defects and their anatomical location. 
With more detailed post-processing of the entire time resolved data, quantitative assessment of contrast 
passage kinetics can be made. Pulmonary blood flow (PBF), pulmonary blood volume (PBV) and mean 
transit time (MTT) can then be quantified and parametric maps of these metrics can be generated from 
voxel-wise analysis. For absolute quantitative analysis an arterial input function (AIF) is measured in a large 
feeding artery, often the main pulmonary artery for lung imaging (3).  
Once the AIF has been established, the signal time curve of a voxel can be converted to 
concentration time course from the assumption of a linear relationship between signal intensity and 
contrast concentration. A model free approach using the following equation can be used: 
ܥሺݐሻ ൌ ݇ ܵሺݐሻ െ ܵ଴ܵ଴  
Where S(t) is the signal time-course, S0 is the mean signal before contrast enhancement and k is an 
unknown constant. For absolute quantitative analysis,T1 mapping is required in order to convert signal 
intensity to contrast agent concentration (mmol/litre (mM)). One method of T1 mapping used in 
quantitative perfusion analysis is the variable flip angle approach. Using a Levenberg-Marquardt fitting 
algorithm tissue density at equilibrium (m0) and T1 relaxation at equilibrium can be calculated via: 
ݏሺߙሻ ൌ ݉଴  ߙ  ? െ ܧ ?଴ ? െ ߙ Ǥ ܧ ?଴ 
Where ܧ ?଴ = exp(-TR.R10). TR = repetition time used in acquiring the T1-weighted flip angle images. Most 
ĐŽŵŵŽŶůǇ ƚŚƌĞĞ ǀĂůƵĞƐ ŽĨ ĨůŝƉ ĂŶŐůĞ  ?ɲ ? ĂƌĞ ƵƐĞĚ ŐĞŶĞƌĂůůǇ ŝŶ ƚŚĞ ƌĂŶŐĞ ŽĨ  ?- ? ?ȗ ?  ?post-injection 
longitudinal relation rates R1(t) are then calculated: 
ܴ ?ሺݐሻ ൌ  െ ൬  ?ܴܶ൰ Ǥ ݈݊  ? െ ሺܣ ൅ ܤሻ ? െ ߙǤ ሺܣ ൅ ܤሻ 
tŚĞƌĞɲA? ĨůŝƉĂŶŐůĞ ?A?  ?^ ?ƚ ?  W S(0)]/(M0sin ɲ ? ?A?  ? ?- ܧ ଴)/(1  W ĐŽƐɲܧ ?଴). Gadolinium concentration 
maps can then be calculated using the equation: 
ܥሺݐሻ ൌ  ܴ ?ሺݐሻ െ ܴ ?଴Ը ?  
Where Ը ?is the experimental relaxivity of Gadolinium (4.39 s-1 mM-1 at 37 ȗ ?(10). Following contrast 
concentration mapping the concentration time-curves are fitted using the Gamma variate function: ܥሺݐሻ ൌ ܭሺݐ െ ܣܶሻܽ݁ െ ሺݐ െ ܣܶሻܾ 
Where K is a constant scale factor, t is time after injection, AT is appearance time of the contrast agent 
in the voxel and a/b are arbitrary parameters. It is worthwhile noting that for gadolinium based contrast 
agents, unlike iodinated contrast agents, contrast concentration and signal intensity are not linearly related at 
higher concentrations. Constant K is related to tissue density, imaging sequence parameters, contrast agent 
and inspiration level. Hence, it is important that these are kept constant during the experiment (11). 
Following the indicator dilution theory (12), once the concentration time course of the AIF is known, 
CAIF(t), pulmonary blood flow (PBF) can be calculated: 
ܥ௏ைூሺݐሻ ൌ ܲܤܨ න ܥ஺ூிሺ߬ሻǤ ܴሺݐ െ ߬ሻ݀߬௧଴ ൌ ܲܤܨሾܥ௔ሺݐሻ ٔ ܴሺݐሻሿ 
Where CVOI(t) is the contrast time course of the region of interest, R is the concentration of contrast 
remaining at time t and ٔ denotes the convolution integral (11,13). Pulmonary blood volume (PBF) and 
mean transit time (MTT) are defined as (13):  
ܲܤܸ ൌ  ׬ ܥ௏ைூሺݐሻ݀ݐஶ଴׬ ܥ஺ூிሺݐሻ݀ݐஶ଴  
ܯܶܶ ൌ ܲܤܸܲܤܨ 
Noise filtering is required before these calculations can be reliably made (11) since the inherent image SNR 
is low. In order for perfusion quantification, it is assumed that there is a linear relationship between signal 
and concentration. This is not a true assumption and linearity is only seen in a small range of low 
concentrations of contrast. This is a particular problem for the AIF as the contrast passes in a compact 
bolus (i.e. high concentration) (14). A robust contrast administration protocol is therefore paramount. One 
method for overcoming this is to use a smaller dose of contrast such as 0.05ml/kg at a rate of 4ml/second 
as suggested above. This has the advantage of only requiring a single injection, but with a reduction in SNR 
in the perfusion image. Another method is to use 2 boluses: a low dose injection to calculate the AIF and a 
second larger dose to give better SNR in the lung perfusion image (15). When using this split bolus 
technique the AIF must be recalculated to match the bolus used in the lung imaging part of the sequence. 
As contrast kinetics are involved, the bolus used to calculate the corrected AIF is shifted by injection 
ĚƵƌĂƚŝŽŶʏ (16): 
ܥ஺ூிሺݐሻ ൌ  ෍ ܥ௣ሺݐ ൅ ݍ߬ሻ௏ ௏೛ ?  
It is also important to ensure that there is sufficient time between the first and second bolus to allow for 
wash-out of contrast. 
NON-CONTRAST ENHANCED MRA AND PERFUSION IMAGING 
 
Long acquisition times and problems with artefacts, such as motion, have limited the use of non-
contrast enhanced MRA. Improving MR technologies, concerns about the use of gadolinium from the risk 
of nephrogenic systemic fibrosis (17) and the desire for non-invasive techniques for paediatrics have 
increased the motivation for non-contrast enhanced methodology for MR perfusion and angiography.  
Double inversion recovery fast spin echo (DIR FSE) imaging, also known as black blood imaging, 
provides images of the pulmonary vasculature where the flowing blood returns no signal. This is 
particularly useful in the assessment of slow flow or thrombo-embolic disease, which are shown as an area 
of high signal intensity surrounded by the low signal intensity of flowing blood. The vessel walls are also 
well visualised.  
ECG gated 3D partial-Fourier Fast Spin Echo (FSE) sequences utilise the difference between fast flow 
and slow flow on T2 signal. In systole, arterial flow is fast and causes a void of T2 signal, whereas in 
diastole, flow is reduced and returns high T2 signal. Venous systems have slow flow in systole and diastole. 
Hence, a subtraction image of the systolic from diastolic image gives high T2 signal in the arterial system 
(18). This method requires ECG gating to allow separation of the diastolic and systolic images, and brings 
with it the risk of mis-registration.  
Balanced steady-state free procession (bSSFP) produces images with the signal proportional to the 
T2/T1, through refocusing gradient echoes and alternating phases of RF pulses to create a coherent steady 
state. The TR must be kept very short as bSSFP is susceptible to field inhomogeneity (19). SSFP is 
particularly useful in imaging the blood, which has long T2 when compared to the surrounding tissues (3) 
and has short acquisition times allowing for short breath-holds (19). The high contrast between pulmonary 
blood pool and lumen make bSSFP an effective tool for assessment of thrombus when MRA and CTPA are 
inconclusive (20) and a fast 3D bSSFP acquisition provides a quick and contrast free means of generating a 
pulmonary angiogram (21). 
Arterial spin labelling (ASL) images are produced by radiofrequency excitation of the water protons 
in ďůŽŽĚƵƉƐƚƌĞĂŵŽĨƚŚĞ ŝŵĂŐŝŶŐ ĨŝĞůĚŽĨǀŝĞǁƚŚƌŽƵŐŚĂŶ ŝŶǀĞƌƐŝŽŶƉƵůƐĞ ?dŚĞƐĞ  “ƚĂŐŐĞĚ ?ƉƌŽƚŽŶƐ ƚŚĞŶ
flow into the field of view to be imaged (14,18,22). A control image is also taken and the images tend to be 
presented as a subtraction of the control image from the tagged image. ASL in the lungs is challenging as 
ECG gating requires a regular heartbeat (14), but can be improved with newer labelling techniques 
including continuous arterial spin labelling (CASL), pulsed arterial spin labelling (PASL) and a combination as 
pseudo-continuous arterial spin labelling (pCASL) (23). ASL using the spin echo entrapped perfusion image 
(SEEPAGE) allows for a single shot acquisition within 5 seconds. SEEPAGE completely supresses the 
backgrŽƵŶĚƚŝƐƐƵĞ ?ƐŽŽŶůǇƚŚĞ  “ƚĂŐŐĞĚ ? protons flowing into the field of view return signal. This has the 
advantage of requiring no subtraction (so no mis-registration) and allows rapid acquisitions within short 
breath-holds (24). All of these spin-labelling techniques are by nature slice selective methodologies, and 
therefore limited in terms of lung volume coverage.  
Time of flight (TOF) MRA is commonly used in neurovascular and peripheral vascular imaging, but poor 
spatial resolution, sensitivity to motion (cardiac or respiratory), multiplanar flow directionality and 
insensitivity to slow flow and sensitivity to susceptibility artefacts limits the utility of TOF MRA in the lungs 
(25).  
Phase contrast MRA with velocity sensitizing gradients can be used to quantitatively map the blood 
flow in the major vessels in the lungs in 3-dimensions and can provide insight in to pulmonary vascular 
resistance and non-steady and turbulent flow in the pulmonary arteries (1,18). Typical velocity encoding 
settings of venc 150cm/s would be used to map flow in the pulmonary artery but this may need 
adjustment for slower flow in diseases such as pulmonary hypertension where flow velocity is slower and 
directionality is helical. Recent developments with 3D view shared phase contrast methods allow 3D time 
resolved imaging of blood flow in the pulmonary arteries (26). Recent developments with 3D view shared 
phase contrast methods allow for the acquisition of 4D flow  in the pulmonary arteries (26,27).  
Time resolved imaging of the lungs during free breathing with Fourier decomposition (FD) analysis 
can be used as a surrogate method to image lung perfusion without the need for contrast or ECG gating. 
Fourier decomposition has recently been applied to lung ventilation and perfusion imaging (28). During 
inspiration the lungs increase in volume, reducing parenchymal signal, increasing again in expiration. 
During systole, high blood velocity causes dephasing of the MR signal, reducing signal. The respiratory 
changes occur at a rate of 12-20 beats per minute and the cardiac changes at a rate of 60-80 beats per 
minutes on average. The difference in frequencies allows for separation using Fourier Decomposition (FD), 
to give ventilation weighted or perfusion weighted images (29) which have been used for perfusion 
quantification (30).  
CLINICAL APPLICATIONS OF PULMONARY MRA AND PERFUSION 
IMAGING 
 
An area that has had significant interest for MR angiography and perfusion is in the assessment of 
pulmonary emboli (PE)(25), particularly in young or pregnant patients who benefit from the avoidance of 
radiation exposure. Real time MR with SSFP (True FISP) produces T2 weighted images in which blood in the 
pulmonary arteries is bright and thrombus is dark. A major advantage of this method is that it is unaffected 
by patient movement. A study of 39 cases with suspected PE gave sensitivity of 83% and specificity of 100% 
for the diagnosis of acute PE (31). Further studies using contrast enhanced MRA have also shown 
sensitivity similar to that of SPECT and CTPA (32,33) . However, the PIOPED III study, conducted in seven 
centres, assessing 371 patients (104 with PE) using contrast enhanced MRA, was less optimistic. They 
found that 25% of patients had inadequate image quality, with the majority of these due to poor arterial 
opacification and motion artefacts. Sensitivity and specificity for acute PE were 78% and 99%, although this 
is increased when combined with venography (34). The lower spatial resolution of MRA over CTPA may 
account for this low sensitivity. The PIOPED researchers recommend that MRA for acute PE is only 
performed in certain centres who regularly perform it, and only in patients with contraindications to 
standard tests. The perfusion defects from obstruction of the pulmonary vascular bed have a characteristic 
wedge shape. DCE MRI has been shown to have a high agreement with SPECT (35). Quantitative 
assessment of perfusion can also predict the presence of acute PE and predict outcome, with PBF being the 
most accurate parameter (36). Interestingly, two sites (UW-Madison and U of Arizona) have been using 
contrast enhanced MRA for the primary diagnosis of pulmonary embolism in young women and in patients 
with iodinated contrast allergy with good results (32). The negative predictive value of MRA for the 
exclusion of pulmonary embolism is >97%. More recent data recently presented by the UW-Madison group 
has shown even better outcomes (NPV 99%) (37). There is a performance gap between the efficacy 
(sensitivity and specificity of MRA vs CTA for PE detection) of MRA from the PIOPED III study and the real 
world performance of this test (effectiveness). This may be related to the fact that sub segmental PE, 
which are not well seen on contrast enhanced MRA, are not clinically significant.   These results will need 
to be repeated at other sites, but suggest that there has been premature abandonment of this imaging test 
for the primary diagnosis of PE. The use of MRA can also be performed as a follow-up for known 
pulmonary embolism to mitigate the amount of medical radiation for these patients.   
Perfusion MRI may be particularly useful in the assessment of chronic PE. It has been shown that 
MR perfusion can be used to screen for perfusion defects in patients with chronic thrombo-embolic 
pulmonary hypertension (CTPEH) (38) and can differentiate the perfusion patterns of CTEPH and idiopathic 
pulmonary artery hypertension as they have focal defects or diffuse reduction in perfusion respectively 
(39). Further work has shown that contrast enhanced MRA and non-contrast enhanced MRA with SSFP can 
be used to diagnose CTEPH with a high sensitivity, with the SSFP imaging being particularly useful in 
identifying proximal disease, but is limited for sub segmental disease (20). PBF has been shown to improve 
in CTEPH patients who have had pulmonary endarterectomy (40). There is also an increase in MTT in 
patients with pulmonary arterial hypertension (PAH), which shows a modest correlation with mPAP (41,42) 
and in patients with combined emphysema and fibrosis MTT correlates with mean pulmonary artery 
pressure and pulmonary vascular resistance (43). In addition, in patients with PAH, pulmonary transit times 
have been shown to correlate with markers of disease severity, mean right atrial pressure and pulmonary 
vascular resistance (44) and are predictive of mortality at univariate analysis and have equivalent 
prognostic value to invasive measures taken at right heart catheterisation (45). Analysis of pulmonary 
arterial flow is also proving to be useful in pulmonary hypertension. Sanz et al showed that average 
pulmonary arterial velocity showed a strong correlation with mean pulmonary artery pressure (46) and 4D 
phase contrast MRI is also providing insights into the complex flow pattern that occur in pulmonary 
hypertension patients. Reiter et al. showed that patients with pulmonary hypertension have vortices in 
their pulmonary arterial blood flow, whereas healthy volunteers did not. Furthermore they showed a very 
strong correlation between the duration of vertical blood flow and mean pulmonary arterial pressure (47). 
In COPD the mean pulmonary blood flow (PBF), mean transit time (MTT) and pulmonary blood 
volume (PBV) are heterogeneous and decreased (13), likely due to regional hypoxic vasoconstriction. The 
perfusion defects seen in COPD can be differentiated from vascular obstruction as they are not wedge 
shaped (35). One study of 45 patients with COPD showed a high correlation in the distribution of MR 
perfusion defects and parenchymal destruction on CT (48). Patients with emphysema also show a loss of 
the normal physiological increase in PBV that is associated with expiration (49). DCE perfusion scores have 
been shown to correlate with markers of COPD severity: a reduction in PBF and PBV is associated with 
worsening CT emphysema score, airflow limitation and DLCO (50,51). Furthermore, exacerbations of COPD 
are associated with a prolonged MTT and TTP (52). 
In 11 children with cystic fibrosis (CF), it was shown that MRI perfusion defects correlated well with 
parenchymal abnormalities (53). In younger patients the changes are more prominent on perfusion MRI 
than morphological changes on CT, raising the possibility of an early biomarker for disease progression 
(54). Perfusion MRI may be used to monitor response to therapy (54) and differentiate reversible from 
irreversible regions of disease (55). This is particularly useful in CF, as the patients are young and repeated 
exposure to radiation from CT should be reduced. As these patients are young, a technique such as ASL or 
Fourier Decomposition, which require no cannulation or contrast injection would beneficial and have 
shown promising results in young patients. Although they does rely upon good patient compliance (due to 
requirement of breath holds), challenging in young children (56). 
The high spatial resolution of pulmonary MRA allows for the direct assessment of pulmonary 
vascular anatomy. This can be utilised to assess for pulmonary vascular abnormalities such as anomalous 
pulmonary venous return, pulmonary artery atresia and pulmonary artery arterio-venous malformations 
(AVMs) (1,57). Time resolved MRA, such as TRICKs, allows for assessment of right to left shunting (58), 
complementary to pulmonary to systemic (Qp:Qs) shunt assessment using pulmonary and aortic phase 
contrast imaging.  
To date there is very limited information published on the role of perfusion MRI in pulmonary 
fibrosis. Whilst not directly related to perfusion, DCE-MRI can differentiate inflammatory and fibrotic 
lesions: inflammatory predominant biopsies showed early enhancement and fibrotic predominant biopsy 
sites showed late enhancement in 26 cases of fibrotic lung disease (59). Furthermore, a comparison of 27 
systemic sclerosis and 10 healthy patients showed that there was a reduction in PBV corrected for lung 
volume (60). As there is a high incidence of PH in fibrotic lung disease, qualitative and quantitative 
measures of pulmonary perfusion would be an interesting area for future research. 
 Conclusion 
Improvements in MRI technology have triggered increasing interest in pulmonary MR perfusion and 
angiography. Whilst multiple methods of image acquisition are available, the mainstay of current clinical 
use is contrast enhanced MRA and DCE MRI. Modest concerns regarding the widespread use of gadolinium 
based contrast agents and the requirement for IV access have increased interest in non-contrast enhanced 
techniques, although these methods are currently confined to research. Pulmonary MRA and MRI 
perfusion are routinely used in the clinical assessment of patients with pulmonary hypertension (PH). 
There is great potential for the role of MRI to be expanded in the diagnosis and serial assessment of 
patients with pulmonary embolism, cystic fibrosis, COPD and in the assessment of patients with pulmonary 
vascular abnormalities (such as arteriovenous malformations and anomalous venous drainage). Further 
methodological developments of MRI sequences coupled with clinical implementation of some of the 
techniques described, will help to further current understandings of pulmonary and pulmonary vascular 
disease.  
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Figure 1: A diagrammatic representation of the basic principles of MR angiography against perfusion MR  
 
 
 
 
 
MRA: 
x High spatial resolution 
x Lower temporal resolution 
x Structural information 
Perfusion MR: 
x Lower spatial resolution 
x High temporal resolution 
x Functional information 
Figure 2:  
 
 
Legend Figure 2: A maximum intensity projection image from a normal contrast enhanced MR angiogram 
in a healthy volunteer. There is extensive venous contamination on this image, highlighting the importance 
of adequately timing the contrast bolus.  
 
  
Figure 3. 
 
Legend figure 4: A normal MR angiogram showing contrast passage dynamics with 15 consecutive 
maximum intensity projection images with a temporal resolution of 1.0 sec/frame acquired using a spiral 
TRICKS technique. Image reprinted with permission from Wiley (8). © 2009 Wiley-Liss, Inc. 
  
Figure 4: 
 
Legend Figure 4: The time-course of dynamic contrast enhanced MRI showing a single coronal slice in a 
healthy volunteer. The top row of images shows the non-ƐƵďƚƌĂĐƚĞĚ “ƌĂǁ ?ŝŵĂŐĞƐ ?ƚŚĞƐĞĐŽŶĚƌŽǁƐŚŽǁƐ
the subtracted images and the bottom row shows the pulmonary parenchymal signal change over time. 
Please note that the images were acquired with a temporal resolution of 0.5 seconds but are displayed 
with a temporal resolution of 1.5 seconds. 
 
  
Figure 5:  
 
  
Legend Figure 5: Parametric maps of perfusion with a display of the Pulmonary Blood Volume (PBV), 
Pulmonary Blood flow (PBF) and Mean transit time (MTT) derived from post processing of a post contrast 
MR perfusion examination using the arterial input function in a patient with COPD. Please note the 
perfusion heterogeneity on the parametric maps. 
 
 
  
Figure 6: 
 
 
Figure 6 SSFP MRA: Comparison of 2mm slice coronal reconstructed unenhanced CT (a) with a 1.9mm 
isotropic bSSFP MR image (b) and 50mm maximum intensity image projections of the CT (c) and bSSFP MRI 
(d). Reproduced with permission from Wiley (61). © 2009 Wiley-Liss, Inc. 
  
Figure 7:
 
 
Legend Figure 7: Coronal HASTE image in a patient with a left hilar non-small cell lung cancer (a). A coronal 
perfusion weighted SEEPAGE image from more dorsal position (b), shows a large associated perfusion 
defect in the left upper lobe. This may be useful in planning for surgery and radiotherapy. Image reprinted 
with permission from Wiley (24). © 2009 Wiley-Liss, Inc. 
  
 Figure 8  
 
Legend Figure 8:  4D flow mapping vortices of blood flow in the pulmonary trunk showing mean voxel 
velocity and directionality of flow (Image courtesy of Dr Guilhem Collier, University of Sheffield). 
  
Figure 9:  
 
Legend figure 9: Image A shows a coronal TrueFISP image in a patient with right interlobar artery 
pulmonary embolus (arrow). The sagittal perfusion weighted Fourier Decomposition (c) image shows 
perfusion defects in the right upper and lower lobe, with no defect present on the corresponding 
ventilation/density image (b).These images  (b and c)  are   examples of a ventilation perfusion mismatch 
using the Fourier decomposition method.  Images reprinted with permission from Wiley (29). © 2009 
Wiley-Liss, Inc. 
  
Figure 10  
 A 
B 
Legend Figure 10: Twenty year old  female college student presenting with a positive D-dimer to the 
student health service.  3D Contrast enhanced MRA in the coronal projection (A) was performed showing a 
left lower lobe perfusion defect (arrows) and  the axial reformations show (B)  bilateral pulmonary emboli 
(arrows). The patient was sent home on subcutaneous heparin and was advised to stop her oral 
contraception.  
 
